Caseware UK (AP4) 2024.0.164 2024.0.164 truetruetrue2023-10-01trueNo description of principal activitytrue00false 07916512 2023-10-01 2024-09-30 07916512 2022-10-01 2023-09-30 07916512 2024-09-30 07916512 2023-09-30 07916512 2022-10-01 07916512 c:Director1 2023-10-01 2024-09-30 07916512 c:Director1 2024-09-30 07916512 c:Director3 2023-10-01 2024-09-30 07916512 c:Director3 2024-09-30 07916512 c:Director4 2023-10-01 2024-09-30 07916512 c:Director4 2024-09-30 07916512 c:RegisteredOffice 2023-10-01 2024-09-30 07916512 d:CurrentFinancialInstruments 2024-09-30 07916512 d:CurrentFinancialInstruments 2023-09-30 07916512 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 07916512 d:CurrentFinancialInstruments d:WithinOneYear 2023-09-30 07916512 d:ShareCapital 2023-10-01 2024-09-30 07916512 d:ShareCapital 2024-09-30 07916512 d:ShareCapital 2022-10-01 2023-09-30 07916512 d:ShareCapital 2023-09-30 07916512 d:ShareCapital 2022-10-01 07916512 d:CapitalRedemptionReserve 2023-10-01 2024-09-30 07916512 d:CapitalRedemptionReserve 2024-09-30 07916512 d:CapitalRedemptionReserve 2022-10-01 2023-09-30 07916512 d:CapitalRedemptionReserve 2023-09-30 07916512 d:CapitalRedemptionReserve 2022-10-01 07916512 d:RetainedEarningsAccumulatedLosses 2023-10-01 2024-09-30 07916512 d:RetainedEarningsAccumulatedLosses 2024-09-30 07916512 d:RetainedEarningsAccumulatedLosses 2022-10-01 2023-09-30 07916512 d:RetainedEarningsAccumulatedLosses 2023-09-30 07916512 d:RetainedEarningsAccumulatedLosses 2022-10-01 07916512 c:OrdinaryShareClass1 2023-10-01 2024-09-30 07916512 c:OrdinaryShareClass1 2024-09-30 07916512 c:OrdinaryShareClass1 2023-09-30 07916512 c:EntityHasNeverTraded 2023-10-01 2024-09-30 07916512 c:FRS102 2023-10-01 2024-09-30 07916512 c:Audited 2023-10-01 2024-09-30 07916512 c:FullAccounts 2023-10-01 2024-09-30 07916512 c:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 07916512 d:Subsidiary2 2023-10-01 2024-09-30 07916512 d:Subsidiary2 1 2023-10-01 2024-09-30 07916512 6 2023-10-01 2024-09-30 07916512 e:PoundSterling 2023-10-01 2024-09-30 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 07916512









Azimuth Pharma Limited









Annual Report and Financial Statements

For the Year Ended 30 September 2024

 
Azimuth Pharma Limited
 
 
Company Information


Directors
G Silver 
J Maxwell 




Registered number
07916512



Registered office
Suite A, Greenway House
Larkwood Way

Tytherington Business Park

Macclesfield

United Kingdom

SK10 2XR




Independent auditor
Forvis Mazars LLP
Chartered Accountants & Statutory Auditor

One St Peter's Square

Manchester

M2 3DE





 
Azimuth Pharma Limited
 

Contents



Page
Directors' report
 
1 - 2
Independent Auditor's Report
 
3 - 7
Balance Sheet
 
8
Statement of Changes in Equity
 
9 - 10
Notes to the Financial Statements
 
11 - 14


 
Azimuth Pharma Limited
 
 
 
Directors' Report
For the Year Ended 30 September 2024

The directors present their report and the audited financial statements of Azimuth Pharma Limited (the "Company") for the year ended 30 September 2024.

Directors' responsibilities statement

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


select suitable accounting policies for the Company's financial statements and then apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors

The directors who served during the year were:

A Medley (resigned 19 April 2024)
G Silver (appointed 15 February 2024)
J Maxwell (appointed 15 February 2024)

Going concern

The financial statements have been prepared on a going concern basis. The following paragraphs set out the basis of which the directors have reached their conclusion.
The Company has net current liabilities of £70,469 
(2023:  £70,469) and net assets of £456,167 (2023: £456,167) at
30 September 2024.
Therefore, the directors believe it is appropriate to prepare the accounts to 30 September 2024 on a going concern basis and there will be no adverse effect on solvency for more than 12 months after the date of approval of the financial statements.

Page 1

 
Azimuth Pharma Limited
 
 
 
Directors' Report (continued)
For the Year Ended 30 September 2024


Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:
 
so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and

the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Auditor

The auditor, Forvis Mazars LLPwill be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.
 





J Maxwell
Director

Date: 27 June 2025

Page 2

 
Azimuth Pharma Limited
 
 
 
Independent Auditor's Report to the Members of Azimuth Pharma Limited
 

Opinion


We have audited the financial statements of Azimuth Pharma Limited (the 'Company') for the year ended 30 September 2024, which comprise  the Balance Sheet, the Statement of Changes in Equity and the related notes, including a summary of significant accounting policies 
 
The financial reporting framework that has been applied in their preparation is applicable law
 and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion, the financial statements:


give a true and fair view of the state of the Company's affairs as at 30 September 2024 and of its result for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Page 3

 
Azimuth Pharma Limited
 
 
 
Independent Auditor's Report to the Members of Azimuth Pharma Limited (continued)


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our Auditor's Report thereon. The directors are responsible for the other information contained within the Annual ReportOur opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Directors' Report has been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Directors' Report and from the requirement to prepare a Strategic Report.


Page 4

 
Azimuth Pharma Limited
 
 
 
Independent Auditor's Report to the Members of Azimuth Pharma Limited (continued)


Responsibilities of directors
 

As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 5

 
Azimuth Pharma Limited
 
 
 
Independent Auditor's Report to the Members of Azimuth Pharma Limited (continued)


Auditor's responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. 
Based on our understanding of the Company and its industry, we considered that non-compliance with the following laws  
and regulations might have a material effect on the financial statements: anti-money laundering regulation. 
 
To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks  
of material misstatement in respect to non-compliance, our procedures included, but were not limited to: 
• Inquiring of management and, where appropriate, those charged with governance, as to whether the Company is in 
 compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws   and regulations;
• Inspecting correspondence, if any, with relevant licensing or regulatory authorities;
• Communicating identified laws and regulations to the engagement team and remaining alert to any indications of 
 non-compliance throughout our audit; and
• Considering the risk of acts by the Company which were contrary to applicable laws and regulations, including    fraud.
 
We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such  
as: tax legislation and the Companies Act 2006. 
 
In addition, we evaluated the directors' and management’s incentives and opportunities for fraudulent manipulation of the  
financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates and significant one-off or unusual transactions. 
 
Our audit procedures in relation to fraud included but were not limited to: 
• Making enquiries of the directors and management on whether they had knowledge of any actual, suspected or    alleged fraud;
• Gaining an understanding of the internal controls established to mitigate risks related to fraud;
• Discussing amongst the engagement team the risks of fraud; and
• Addressing the risks of fraud through management override of controls by performing journal entry testing.
 
There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and  
detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection  
of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or the override of  
internal controls.



A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's Report.


Page 6

 
Azimuth Pharma Limited
 
 
 
Independent Auditor's Report to the Members of Azimuth Pharma Limited (continued)


Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.





Christopher Martin (Senior Statutory Auditor)
for and on behalf of Forvis Mazars LLP
Chartered Accountants & Statutory Auditor
One St Peter's Square
Manchester
M2 3DE

27 June 2025
Page 7

 
Azimuth Pharma Limited
Registered number: 07916512

Balance Sheet
As at 30 September 2024

2024
2023
Note
£
£

Fixed assets
  

Investments
 6 
526,636
526,636

  
526,636
526,636

  

Current liabilities
  

Creditors: amounts falling due within one year
 7 
(70,469)
(70,469)

Net current liabilities
  
 
 
(70,469)
 
 
(70,469)

Total assets less current liabilities
  
456,167
456,167

  

Net assets
  
456,167
456,167


Capital and reserves
  

Called up share capital 
 8 
5
5

Capital redemption reserve
 9 
5
5

Profit and loss account
 9 
456,157
456,157

  
456,167
456,167


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




J Maxwell
Director

Date: 27 June 2025

The notes on pages 11 to 14 form part of these financial statements.

Page 8

 
Azimuth Pharma Limited
 

Statement of Changes in Equity
For the Year Ended 30 September 2024


Called up share capital
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£

At 1 October 2023
5
5
456,157
456,167


Comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
-
-


At 30 September 2024
5
5
456,157
456,167


The notes on pages 11 to 14 form part of these financial statements.

Page 9

 
Azimuth Pharma Limited
 

Statement of Changes in Equity
For the Year Ended 30 September 2023


Called up share capital
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£

At 1 October 2022
5
5
456,157
456,167


Comprehensive income for the year
-
-
-
-


Total comprehensive income for the year
-
-
-
-


At 30 September 2023
5
5
456,157
456,167


The notes on pages 11 to 14 form part of these financial statements.

Page 10

 
Azimuth Pharma Limited
 
 
 
Notes to the Financial Statements
For the Year Ended 30 September 2024

1.


General information

Azimuth Pharma Limited is a private company limited by share capital. The Company is incorporated in England, company number 07916512. The address of the registered office and principal place of business is Suite A, Greenway House, Larkwood Way, Tytherington Business Park, Macclesfield, United Kingdom, SK10 2XR.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Financial reporting standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Bioscript Holdings Limited as at 30 September 2024 and these financial statements may be obtained from Suite A, Greenway House, Larkwood Way, Tytherington Business Park, Macclesfield, United Kingdom, SK10 2XR.

 
2.3

Exemption from preparing consolidated financial statements

The Company is a parent company that is also a subsidiary included in the consolidated financial statements of its immediate parent undertaking established under the law of an EEA state and is therefore exempt from the requirement to prepare consolidated financial statements under section 400 of the Companies Act 2006.
The Company is included in the consolidation of Bioscript Holdings Limited and the consolidated financial statements of Bioscript Holdings Limited may be obtained from Suite A, Greenway House, Larkwood Way, Tytherington Business Park, Macclesfield, United Kingdom, SK10 2XR.
 

Page 11

 
Azimuth Pharma Limited
 
 
 
Notes to the Financial Statements
For the Year Ended 30 September 2024

2.Accounting policies (continued)

 
2.4

Going concern

The financial statements have been prepared on a going concern basis. The following paragraphs set out the basis of which the directors have reached their conclusion.
The Company has net current liabilities of £70,469
 (2023: £70,469) and net assets of £456,167 (2023: £456,167) at 30 September 2024.
Therefore, the directors believe it is appropriate to prepare the accounts to 30 September 2024 on a going concern basis and there will be no adverse effect on solvency for more than 12 months after the date of approval of the financial statements.

 
2.5

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

  
2.6

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Judgements in applying accounting policies and key sources of estimation uncertainty

The preparation of the financial statements requires management to make significant judgements and estimates that
affect amounts recognised for assets and liabilities at the reporting date and the amounts of revenue and expenses
incurred during the period. Actual outcomes may differ from these judgements, estimates and assumptions. The directors believe that judgements, estimates and assumptions do not have a significant risk of causing a material
difference to the carrying amounts of the assets and liabilities within the next financial year.


4.


Auditor's remuneration

Auditor's remuneration of £2,648 (2023: £2,596) relating to the Company were borne by its parent company,
Bioscript Limited.


5.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2023: £Nil).

Page 12

 
Azimuth Pharma Limited
 
 
 
Notes to the Financial Statements
For the Year Ended 30 September 2024

6.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 October 2023
526,636



At 30 September 2024
526,636





Subsidiary undertakings


The following was subsidiary undertakings of the Company:

Name

Registered office

Class of shares

Holding

Fortis Pharma Consulting Limited
Suite A, Greenway House
Larkwood Way
Tytherington Business Park
Macclesfield, United
Kingdom, SK10 2XR
Ordinary
100%


7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Amounts owed to group undertakings
70,469
70,469


The Group has given a guarantee in respect of the loan advance to a Group subsidiary. The maximum potential
liability to the Company as at 30 September 2024 amounted to £26,964,466 
(2023: £23,279,243).

Page 13

 
Azimuth Pharma Limited
 
 
 
Notes to the Financial Statements
For the Year Ended 30 September 2024

8.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



525 (2023: 525) Ordinary shares of £0.01 each
5
5



9.


Reserves

Capital redemption reserve

The capital redemption reserve consists of the nominal value of shares that have been acquired by the Company and cancelled.

Profit and loss account

The profit and loss account includes all current and prior period retained profits and losses.


10.


Controlling party

The immediate parent company is Bioscript Limited, a company registered in England and Wales, company number
13216692, which owns 100% of the called up share capital.
The ultimate parent company is Bioscript Holdings Limited, a company registered in England and Wales, company number 13203898.

Page 14